Stock 1558 YICHANG HEC CHANGJIANG PHARMACEUTICAL CO., LTD.
Add to a list
To use this feature you must be a member
Log inSign up

All News YiChang HEC ChangJiang Pharmaceutical Co., Ltd.

Equities

1558

CNE1000023R6

Market Closed - Hong Kong S.E.
Other stock markets
 09:08:42 28/06/2024 BST 		5-day change 1st Jan Change
9.4 HKD +5.15% Intraday chart for YiChang HEC ChangJiang Pharmaceutical Co., Ltd. +4.10% -0.95%
05-16 YiChang HEC ChangJiang Pharmaceutical Co., Ltd. Proposes Special Dividend CI
05-08 Yichang HEC Still Negotiating Merger Deal with Sunshine Lake Pharma MT

All News

Search
See the results
Unlock all the news: Be the first to know and act before the market!
100% Free Registration
YiChang HEC ChangJiang Pharmaceutical Co., Ltd. Proposes Special Dividend
CI
Yichang HEC Still Negotiating Merger Deal with Sunshine Lake Pharma
MT
Yichang Hec Changjiang Pharmaceutical Updates on Possible Merger with Sunshine Lake Pharma
MT
Yichang Hec Changjiang Pharmaceutical's Net Profit Surges in 2023 as Revenue Jumps
MT
YiChang HEC ChangJiang Pharmaceutical's Profit Surges in 2023
MT
YiChang HEC ChangJiang Pharmaceutical Co., Ltd. Reports Earnings Results for the Full Year Ended December 31, 2023
CI
Yichang Hec Changjiang Pharmaceutical Expects Up to 2,627% Profit Surge in 2023
MT
YiChang HEC ChangJiang Pharmaceutical Co., Ltd. Provides Group Earnings Guidance for the Year Ended 31 December 2023
CI
YiChang HEC ChangJiang Pharmaceutical Co., Ltd. and Sunshine Lake Pharma Enter into Drug R&D Pipeline Cooperation Project Framework Agreement
CI
HEC ChangJiang Pharmaceutical Increases Transaction Limits Under 2 Contracts
MT
HEC ChangJiang Pharmaceutical's Insulin Injection Cleared for Market Launch in China
MT
YiChang HEC ChangJiang Pharmaceutical Co., Ltd. Receives Approval for Mixed Protamine Human Insulin Injection from the China National Medical Products Administration
CI
YiChang HEC ChangJiang Pharmaceutical Co., Ltd.Approves Announces Executive Changes
CI
HEC ChangJiang Pharmaceutical Returns to Profit on Surge in Anti-Viral Drug Sales
MT
YiChang HEC ChangJiang Pharmaceutical Co., Ltd. Reports Earnings Results for the Half Year Ended June 30, 2023
CI
China Greenlights New Drug Application for HEC ChangJiang Pharmaceutical's Hepatitis C Drug
MT
National Medical Products Administration of the People's Republic of China Accepts the Application for Launching Yiqibuvir Tablets
CI
YiChang HEC ChangJiang Pharmaceutical Co., Ltd. Announces Resignation of Chen Yangui as Executive Director
CI
HEC ChangJiang Pharmaceutical Forecasts Surge in H1 Profit; Shares Rise 5%
MT
YiChang HEC ChangJiang Pharmaceutical Co., Ltd. Provides Earnings Guidance for the Six Months Ended June 30, 2023
CI
No results for this search
All News Analyst Reco. Highlights Insiders Transcripts Press Releases Official Publications Other languages Trading Ideas MarketScreener Editorial Features MarketScreener Strategies

Filters

Search

Announcement Date

Since

Until

  1. Stock Market
  2. Equities
  3. 1558 Stock
  4. News YiChang HEC ChangJiang Pharmaceutical Co., Ltd.